Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 6Crohn Disease 4Colitis, Ulcerative 4Colitis 4Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Inflammatory Bowel Diseases 3Arthritis, Rheumatoid 3Urogenital Neoplasms 2Inflammation 2Hematologic Neoplasms 2Graft vs Host Disease 2Fatigue 2Depressive Disorder, Major 2Depression 2Cachexia 2Anorexia 2Vasculitis 1Takayasu Arteritis 1Syndrome 1Stroke 1Stevens-Johnson Syndrome 1Skin Neoplasms 1Recurrence 1Rare Diseases 1Pemphigoid, Benign Mucous Membrane 1Pancreatic Neoplasms 1Lymphoma 1Kidney Transplantation 1Hypertension 1

Interventions

Oxaliplatin 6Irinotecan 5Fluorouracil 5Bevacizumab 4Leucovorin 3Drug Therapy 3Capecitabine 35,10-methylenetetrahydrofolic acid 3pembrolizumab 2Ocoxin 2Magnetic Resonance Spectroscopy 2Levoleucovorin 2Folfox protocol 2Cyclophosphamide 2Cetuximab 2trifluridine tipiracil drug combination 1sintilimab 1repotrectinib 1pralsetinib 1penpulimab 1napabucasin 1huachansu 1guadecitabine 1golotimod 1encorafenib 1alectinib 1XELOX 1Ursodeoxycholic Acid 1Surveys and Questionnaires 1S-1 plus cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gastrointestinal Diseases × Infliximab × Clear all
NCT00004941 2015-03-25

Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease

FDA Office of Orphan Products Development

Phase 3 Completed
94 enrolled
Gastrointestinal

Crohn Disease, Gastrointestinal Diseases, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡